HeartBeam, Inc. (BEAT) Accepted Into FDA TAP Pilot for 3D ECG MI Assessment

What happened

HeartBeam was accepted into the FDA's TAP Pilot for its 3D ECG heart attack assessment technology, following Breakthrough Device Designation. TAP gives proactive FDA guidance and payer engagement but does not guarantee authorization or coverage.

Confirmed

Global impact / market context

The pilot may shorten the path to market and start payer talks earlier, which could speed adoption after clearance. HeartBeam also expects no new hardware, potentially lowering development cost, risk, and time to a pivotal study and submission.

Analyst inference

This adds to recent regulatory momentum after Breakthrough status. The article estimates a large heart attack assessment market, defining possible upside, but revenue still depends on successful trials, clearance, supportive evidence, and coverage decisions from payers.

Analyst inference

What to watch

1. HeartBeam expects its pivotal study to start in the first quarter of 2027, which is the next major milestone. Investors can time catalyst risk around enrollment progress and FDA-aligned study design. Confirmed
2. TAP connects to payers including CMS, which means the Centers for Medicare and Medicaid Services. Early coverage talks could speed adoption after clearance if the evidence is supportive. Proposed
3. Watch whether the pivotal study design wins FDA alignment, enrollment starts on time, and results are strong. Coverage progress would then determine whether estimated market size turns into actual revenue. Analyst inference

Evidence

• Original source link unavailable